LegisTrack
Back to all bills
HRES 449119th CongressIntroduced

Supports the designation of "ALS Awareness Month".

Introduced: May 29, 2025
Healthcare
Standard Summary
Comprehensive overview in 1-2 paragraphs

H. Res. 449 is a non-binding House Resolution introduced on May 29, 2025, by Rep. Crow (with Reps. Calvert, Sewell, and Fitzpatrick as co-sponsors) and referred to the Committee on Energy and Commerce. The resolution states the House’s support for designating “ALS Awareness Month.” It lays out basic facts about amyotrophic lateral sclerosis (ALS) — a progressive neurodegenerative disease with a typical life expectancy of 2 to 5 years after diagnosis, no known cure as of introduction, and burdens that affect patients and families — and commits the House to actions aimed at improving access to treatments, identifying causes and risk factors to prevent new cases, empowering people with ALS, reducing the burdens of living with the disease, and ensuring high-quality services and supports. The text emphasizes awareness, research, and patient- and caregiver-focused concerns, while not creating new programs or funding commitments by itself. As a resolution, the measure is primarily a symbolic expression of congressional support and intent, rather than a law that would mandate funding or establish new programs. It signals a policy preference for increased awareness, research, early treatment access, and support services for people with ALS and their caregivers.

Key Points

  • 1Designates and supports “ALS Awareness Month” as a national focus.
  • 2Affirms commitment to access to effective treatments, identifying risk factors and causes to prevent new cases.
  • 3Commits to empowering people with ALS to engage with the world on their terms.
  • 4Seeks to reduce physical, emotional, and financial burdens on people living with ALS and their caregivers.
  • 5Commends families, friends, organizations, volunteers, researchers, and caregivers nationwide for their efforts to improve life expectancy and quality of life for ALS patients and to advance treatments and cures.

Impact Areas

Primary group/area affected: People living with ALS and their caregivers and families.Secondary group/area affected: Veterans (noted as having a higher likelihood of ALS diagnosis) and the broader ALS community, including patient organizations and healthcare providers.Additional impacts: Increased awareness and public support for ALS research and treatment, potential influence on future policy discussions or funding decisions related to ALS research and patient services; no new mandatory spending or specific regulatory changes are enacted by this resolution.
Generated by gpt-5-nano on Oct 3, 2025